Many investigators are interested in combining biomarkers to predict a binary outcome or detect underlying disease. This endeavor is complicated by the fact that many biomarker studies involve data from multiple centers. Depending upon the relationship between center, the biomarkers, and the target of prediction, care must be taken when constructing and evaluating combinations of biomarkers. We introduce a taxonomy to describe the role of center and consider how a biomarker combination should be constructed and evaluated. We show that ignoring center, which is frequently done by clinical researchers, is often not appropriate. The limited statistical literature proposes using random intercept logistic regression models, an approach that we demonstrate is generally inadequate and may be misleading. We instead propose using fixed intercept logistic regression, which appropriately accounts for center without relying on untenable assumptions. After constructing the biomarker combination, we recommend using performance measures that account for the multicenter nature of the data, namely the center-adjusted area under the receiver operating characteristic curve. We apply these methods to data from a multicenter study of acute kidney injury after cardiac surgery. Appropriately accounting for center, both in construction and evaluation, may increase the likelihood of identifying clinically useful biomarker combinations.
Introduction
Biomedical investigations are often conducted in multiple centers (e.g. hospitals, clinics, providers). For etiologic and therapeutic studies, there is a substantial literature on the challenges of a multicenter study design. These challenges include correlations among observations from the same center and the effect of differences across centers. 1 The literature on multicenter studies is especially extensive for randomized trials, where the need for careful design and analysis of such studies is widely acknowledged.
that center does not generalize to patients from centers not in the study, so a prediction instrument that used center as a predictor would not be broadly applicable. Recognizing this situation, it seems some biomarker investigators decide to simply ignore the fact that their data come from multiple centers. As we will demonstrate, ignoring center can produce misleading or undesirable results. Although center cannot be used as a predictor, it generally must be accounted for. However, not all methods for accounting for center are suitable for biomarker studies, and we will illustrate shortcomings with some existing methods.
We will consider the role that center can play in multicenter biomarker studies, including proposing a taxonomy that distinguishes different ways that center can be important and providing guidance to researchers on identifying the role center may play in their studies. We assess the impact of ignoring center and evaluate existing approaches for accounting for center in biomarker studies. Finally, we propose suitable methods for constructing and evaluating biomarker combinations using data from multiple centers. We restrict attention to biomarkers that will be used to identify individuals likely to have (in the diagnostic setting) or develop (in the prognostic setting) some clinical outcome; such biomarkers are sometimes referred to as ''prognostic'' or ''diagnostic'' biomarkers, as opposed to biomarkers used to predict response to treatment, which are often called ''predictive'' biomarkers.
This work was motivated by the Translational Research Investigating Biomarker Endpoints in Acute Kidney Injury (TRIBE-AKI) study. The TRIBE-AKI study involves 1219 cardiac surgery patients at six centers in North America. 5 The participants were followed for diagnosis of post-operative acute kidney injury (AKI). For each patient, blood and urine were collected at multiple time points pre-and post-operatively, and about two dozen biomarkers were measured at each time point. AKI is typically diagnosed via changes in serum creatinine but these changes often do not happen until several days after the injury. 5 One goal of the study is to identify a combination of post-operative biomarkers that can provide an earlier diagnosis of AKI.
Notation and terminology
We discuss existing methods for (i) modeling clustered data and (ii) adjusting for covariates in evaluating performance. We then apply these ideas to the multicenter setting, where center can be thought of as both a clustering variable and a covariate. Below, we primarily use the term ''cluster,'' though this is (for our purposes) interchangeable with ''covariate.'' Let C indicate cluster and suppose the population consists of M clusters where cluster c has N c observations, c ¼ 1, . . . , M. Further suppose that we observe data from m of these clusters with n c observations from cluster c, giving n total observations. We consider a p-dimensional vector of predictors X and a binary outcome D. Cases (individuals who have or will develop the outcome) are denoted by either D ¼ 1 or the subscript D, while controls (individuals who do not have or will not develop the outcome) are denoted by either D ¼ 0 or the subscript " D. Let ðX, DÞ be the predictors and outcome for an arbitrary observation. We use the subscript i on X and D to denote the predictors and outcome, respectively, for the ith observation. We use the superscript c on X and D to denote the predictors and outcome, respectively, for an observation from cluster c. We denote the collection of predictors and outcomes for observations in cluster c as ðX c , D c Þ. In general, in the clustered data setting, predictors may be constant for all observations in a cluster (often called cluster-level, cluster-constant, or between-cluster predictors), may vary across observations in a cluster (called cluster-varying or within-cluster predictors), or may vary both within and between clusters. We focus on predictors that have at least some variation within clusters. Throughout, we will assume a non-trivial cluster-specific prevalence of D; that is, PðD ¼ 1jC
3 Models for clustered data 3.1 Random intercept logistic regression
The random intercept logistic regression (RILR) model can be written as
Typically, it is assumed that b c $ Nð0, 2 Þ so 2 is an additional parameter in this model. If we view the random intercept b c as z c , where z c $ iid Nð0, 1Þ, is the regression coefficient for this standardized omitted (cluster-level) predictor. 6 In that sense, b c is generally ''interpreted as the combined effects of omitted clusterlevel predictors.'' 
Assumption (A1) can be written as f ðb c jX c Þ ¼ f ðb c Þ, which is a fairly strong assumption in the non-randomized setting. 6 In particular, this assumption is often implausible when the distribution of the predictors varies by cluster.
Estimates
It is important to distinguish between marginal and conditional modeling approaches: the conditional (or clusterspecific) approach, for example, RILR, involves modeling the probability distribution of D as a function of predictors and cluster-specific parameters (e.g. cluster-specific intercepts), while the marginal (or populationaveraged) approach involves modeling the marginal expectation of D as a function of predictors. 10 Due to the inclusion of cluster-specific parameters, parameter interpretation under the conditional approach is with respect to cluster. 10 For predictors that vary within clusters, conditional methods are often more appropriate than marginal methods, such as generalized estimating equations. 10 In particular, conditional approaches are most useful when there is interest in estimating the association between the predictor and the outcome without the influence of cluster differences.
Predictors frequently have both a between-and within-cluster component; that is, they vary both within and between clusters. 11 Estimates obtained via conditional methods are generally interpreted as estimates of the withincluster association, i.e. the association within each cluster, averaged across clusters; this is typically what researchers are trying to estimate when they use these methods with predictors that vary within clusters. 1, 12, 13 However, as discussed below, estimated coefficients obtained from RILR may not actually represent the withincluster association: depending upon the nature of the data, the resulting estimates are often a combination of within-and between-cluster variations. 1, [9] [10] [11] [13] [14] [15] [16] Importantly, between-cluster differences are likely to include the effects of cluster-constant confounders. 13 
Violations of assumptions
First we consider (A1); that is, independence of b c and X c . In the context of a randomized multicenter clinical trial, the assumption holds since the distribution of the predictor, treatment, is the same across centers in large samples. 1, 11 However, as noted above, it is often the case that predictors are not purely within-cluster and instead have both a between-cluster component and a within-cluster component. 11, 17, 18 When such predictors are included in a RILR model, the assumption that b c and X c are independent may not hold, leading to distortions of the association of interest. 11, 17 As a concrete example, suppose the following model holds for the predictor X:
where b 0 c $ Nð0, 2 Þ and hðÁÞ is some cluster-level summary of X c such that X À hðX c Þ has the same distribution across clusters. Here, X À hðX c Þ corresponds to the within-cluster component of X and hðX c Þ corresponds to the between-cluster component of X. If the distribution of the predictor is the same across clusters, then ð B À W ÞhðX c Þ will be constant in large samples, and can be combined with the fixed intercept 0 . However, if the distribution of the predictor varies across clusters such that hðX c Þ varies and the RILR model given in equation (1) is fit to the data, b c ¼ b
Results from research on omitted variable bias indicate that when equation (2) holds, and equation (1) is fit to the data, the estimate of W will be a combination of the within-and between-effects, B and W . 11 Importantly, the combination of within-and between-effects, if these effects differ, is not of substantive interest, as it lacks clinical relevance. 1, 11 Even in situations where it is thought that the between-and within-cluster effects are reasonably close to one another, there is the potential for differential confounding at the between-versus within-cluster level; thus, using both within-and between-cluster comparisons to estimate the within-cluster effect is problematic. 13, 19 If cluster-level factors are associated with the predictors, as is often true in observational studies, the distribution of the predictors will vary across clusters, which may lead to correlation between the random intercepts and the predictors. 7, 16 This issue is often called ''confounding by cluster'' since the within-cluster association, W , is distorted by the between-cluster association, B 1,9,17,20, 21 ; in the econometrics literature, it is called the ''endogenous covariates problem.'' 7 In our example, omitting hðX c Þ leads to correlation between b c and X c , which, as described by Greenland et al., has the effect of confounding W . 22 Thus, confounders are ''now covariates that 'explain' the correlation between'' b c and X c , 22 namely, the cluster-level variable hðX c Þ. Assumption (A2) requires that the random cluster-specific intercepts be independently and identically distributed according to a normal distribution with mean zero and variance 2 . Broadly speaking, misspecifications of the random intercept distribution may lead to bias in the estimate of the fixed intercept and the coefficients for cluster-level variables but typically do not have a large effect on the estimates for cluster-varying predictors. 6, 18, 23, 24 One solution that has been proposed to address violations of assumption (A1) is to decompose predictors into a between-cluster component and a within-cluster component. 9, 11, 14, 16, 18, 19, 25, 26 In the context of model (2), this means fitting a model with hðX c Þ and X as predictors. When hðX c Þ ¼ " X c , the cluster mean, this approach is called the ''poor man's'' method. 11 Using the cluster mean may be overly simplistic 17 and more flexible methods have been proposed based on modeling b c as a function of X c . 27 Of course, these methods require that the model for b c be correctly specified. 16, 26, 27 3.1.4 Efficiency RILR is often touted as being more efficient than alternative methods due in part to the assumption that b c has some (parametric) distribution. 12, 28 In addition, RILR can use both between-and within-cluster comparisons to estimate coefficients, which allows it to use more information in estimating these parameters. 8, 9, 12, 29 Some studies have found reduced efficiency when the distribution of the random intercept is not normal and normality is assumed. 30 
Fixed intercept logistic regression
Fixed intercept logistic regression (FILR) can be used to model clustered data by including a fixed intercept for each cluster. These models are a special case of generalized linear models. We consider two variants of FILR: conditional (cFILR) and unconditional (uFILR). Both cFILR and uFILR have the same model form:
where c 0 represents a cluster-specific intercept. The conditioning on c 0 in equation (3) is only necessary if c 0 is random. cFILR and uFILR differ in their approach to estimation: uFILR relies on the full likelihood, while cFILR uses a conditional likelihood, conditioning on the number of cases in each cluster. 31 This allows cFILR to avoid the incidental parameters problem when the number of clusters is large. 31 
Assumptions
In the econometrics literature, the distinction between RILR and FILR is based not on whether the cluster-specific intercepts are fixed or random, but whether they are independent of the predictors. 8 Thus, the key assumption for FILR is 8, 9 (B1) Conditional on X c , D If the c 0 are random, then they must be independent across clusters and assumption (B1) must additionally condition on c 0 . 8, 9 3.2.2 Estimates FILR consistently estimates the within-cluster effect of predictors that vary within clusters, provided (B1) is satisfied and model (3) holds. 11, 12, 15, 17 Thus, this method avoids the issue of confounding by cluster; in fact, the resulting estimates are not subject to confounding by any unmeasured cluster-constant variable. 13, 17 For both uFILR and cFILR, only within-cluster comparisons are used to estimate the coefficients, and, since clusters for which all observations have D ¼ 1 or all observations have D ¼ 0 (we call these ''concordant clusters'') do not contribute any information to the estimation of the within-cluster effect, they are not used in estimation. 8, 12 This is also true of clusters that are concordant on the predictors, though this situation is unlikely when there are multiple and/or continuous predictors.
Efficiency
Many investigators are hesitant to use FILR since the exclusion of concordant clusters could reduce efficiency. 11 However, previous research has shown that cFILR provides estimates that are efficient relative to RILR for predictors that vary predominantly within-clusters. 19, 32 Indeed, as pointed out by Neuhaus and Kalbfleisch, for predictors with between-and within-cluster components, the increased efficiency of estimates from RILR that is sometimes observed is often largely due to the assumption of common within-and between-cluster effects.
11 If these effects are indeed equal, there will be some efficiency gain from using RILR since this approach uses both within-and between-cluster variations to estimate the coefficients. 19 However, as noted above, using both types of variation in estimation is generally not recommended since the between-and within-cluster effects may not be equal and the potential exists for differential confounding. Furthermore, as concordant clusters contribute to between-cluster variation and often exhibit strong between-cluster effects, they have the potential to heavily distort the estimated coefficients for predictors that vary within clusters if RILR is used. 14, 15 Finally, uFILR involves estimating m cluster-specific intercepts, which may lead to reduced efficiency relative to RILR, particularly when m is large relative to the total sample size.
Evaluating the performance of a predictor
Suppose we have a predictor Z and are interested in evaluating its performance. Without loss of generality, we will assume that higher values of Z are more indicative of D. We focus on discrimination, since determining the discriminative ability of a predictor is often the first step in developing a clinically useful diagnostic or prognostic tool. Discrimination is the ability of Z to separate cases and controls, and is commonly assessed via the area under the receiver operating characteristic (ROC) curve (AUC). The ROC curve plots the true positive rate, the proportion of correctly classified cases, versus the false positive rate, the proportion of incorrectly classified controls, over the range of possible thresholds for Z. 33 The ROC curve for a useless predictor is the 45 line, and the corresponding AUC is 0.5. 33 The ROC curve for a perfect predictor reaches the upper left-hand corner of the unit square, and the AUC for such a predictor is 1. 33 The AUC has a probabilistic interpretation: it is the probability that, for a randomly selected case and control, the value of Z for the case is higher than the value of Z for the control, that is, 33 In practice, we can estimate the AUC empirically:
where 1ða 4 bÞ is 1 if a 4 b and 0 otherwise. 33 Covariate effects could influence the evaluation of the predictor Z; in particular, associations between Z and the covariate could allow the covariate to contribute to or attenuate the discriminatory accuracy of Z. 34 In order to prevent the covariate from affecting the assessment of the discriminatory accuracy of Z, the covariate-adjusted AUC should be evaluated. The covariate-adjusted ROC (aROC) and corresponding covariate-adjusted AUC (aAUC) for a discrete covariate C, proposed by Janes and Pepe, can be written as aROC Z and aAUC Z , respectively, where
where t denotes the false positive rate, ROC ZjC¼c and AUC ZjC¼c denote the covariate-specific ROC and AUC, respectively, and w c ¼ PðC ¼ cjD ¼ 1Þ denotes the distribution of the covariate among cases. Thus, the aAUC is a weighted average of the covariate-specific AUCs, where the weights correspond to the proportion of cases with each covariate value. 35, 36 In practice, AUC ZjC¼c is estimated empirically:
The empirical aAUC estimate is then . Using the distribution of the covariate among cases to summarize the covariate-specific AUCs is compelling because the resulting measure is the area under the ROC curve corresponding to the true positive rate based on covariate-specific thresholds; these covariate-specific thresholds are chosen such that the false positive rate is the same for each value of the covariate. 35 That is, we can write aROC Z ðtÞ ¼ PðZ 4 g c ðtÞjD ¼ 1Þ, where g c ðtÞ is the covariate-specific threshold giving a false positive rate of t for the covariate value c. 35 When the same data are used to construct a combination and evaluate its performance, the resulting estimate of performance is optimistic. 37 This can be addressed by using a bootstrapping procedure to estimate the degree of optimism. 37, 38 Bootstrapping assumes observations are exchangeable, which may not be reasonable when the data are clustered; thus, bootstrap resampling of clusters has been suggested. 1, 36, 39, 40 However, Bouwmeester et al. found similar results for the average cluster-specific AUC whether resampling was done on clusters or individual observations. 39 
Biomarker combinations in multicenter studies
Now, our predictors consist of a collection of biomarkers, and both the covariate and the cluster variable are center.
When the data come from a single center, a common practice is to first construct a combination of the biomarkers, often using logistic regression, and evaluate its performance using measures such as the AUC. With more than one center, it is important to consider how to appropriately accommodate center in both the construction and evaluation of biomarker combinations.
Throughout, we focus on constructing a single biomarker combination; that is, we do not allow the relationship between the biomarkers and the outcome to vary across centers. In the clinical trial setting, assessing treatment-bycenter interactions is usually not part of the primary analysis. 29 Analogously, in the diagnostic and prognostic settings, it is preferable to give a single combination that is not center-specific, as this would make combination development highly localized. We focus on constructing linear combinations via the logistic regression framework. While this may seem restrictive, Pepe et al. noted that the class of linear combinations is actually quite large (taking into consideration possible biomarker transformations and interactions) and the logistic form is fairly robust. 41 
The role of center
We consider the role of center in the context of two sets of characteristics: We focus on three possibilities for the role of center. We call center a confounder when it affects both the prevalence of D and the biomarker measurements, a case mix variable when it affects only the prevalence of D, and a calibration variable when it affects only the biomarker measurements.
In the TRIBE-AKI study, where the goal is to use biomarkers to diagnose AKI, certain centers may serve particularly unhealthy communities, resulting in differences in biomarker levels across centers; however, these differences may reflect true underlying biology. If factors such as storage and handling of biomarkers and surgical practices are standardized, such that the distribution of biomarkers is similar across centers, conditional on case status, center would be a case mix variable. If, however, these factors vary across centers (e.g. in some centers surgeons use different protocols for fluid administration) in addition to variability in disease prevalence, center would be a confounder. On the other hand, if the populations served by each center are relatively similar in terms of underlying AKI risk, but factors such as surgical protocols vary across centers and lead to variations in biomarker measurements, center would be a calibration variable.
We can also consider an example with prognostic biomarkers. Suppose carotid intima-media thickness is used to predict which patients will experience stroke. If certain centers tend to serve less healthy populations (i.e. those at greater risk for stroke), but practices for measuring carotid intima-media thickness are standardized across centers, then center would be a case mix variable. If the make-up of patients in terms of underlying risk of stroke is similar across centers, but different protocols or imaging tools are used at different centers such that the distribution of intima-media thickness measurements varies across centers, then center would be a calibration variable. If both the composition of patients and intima-media thickness measurement practices vary across centers, then center would be a confounder.
In Figure 1 , we present graphical and probabilistic depictions of center as a case mix variable, a calibration variable, and a confounder for diagnostic or prognostic biomarkers X. Diagnostic biomarkers represent some underlying disease or disease process, i.e. D ! X, while prognostic biomarkers cause some future outcome, i.e. X ! D.
It is important to distinguish center as a confounder, as defined in Figure 1 , from ''confounding by cluster'' in the context of a RILR model. Our use of ''confounding'' in Figure 1 is in line with standard epidemiological notions of confounding, where a variable C distorts the effect of interest, the causal association between X and D. The idea of ''confounding by cluster'' for RILR models, on the other hand, is specific to the RILR framework: ''confounding by cluster'' occurs when the random intercepts and the biomarkers are not independent, leading to distortion of the effect of interest, the within-cluster association. As we will see, there are situations where center is not a confounder by the definitions in Figure 1 , but the random intercepts and the biomarkers are not independent, so the estimates from the RILR model are susceptible to ''confounding by cluster.''
Ignoring center
Clinical researchers frequently ignore center in the construction and/or evaluation of combinations of diagnostic or prognostic biomarkers (e.g. Shapiro et al. 42 and Vuilleumier et al. 43 ). This is likely due to the fact that investigators acknowledge that center should not naı¨vely be included as a predictor, but are not familiar with methods for accommodating center or the repercussions of ignoring it. First, we consider ignoring center in combination construction. Suppose the linear-logistic model holds:
Such a model could arise from the following data-generating model for two biomarkers, X ¼ ðX 1 , X 2 Þ:
where X 1 and X 2 are related to the center-specific AUC for each marker:
where È is the standard normal distribution function and 1 and 2 are the center-specific AUCs for X 1 and X 2 , respectively. Thus, we consider constant center-specific AUCs for X 1 and X 2 , and allow for center effects on biomarker levels via conditional mean shifts (f(c)). Equation (7) gives
where c 0 is a center-specific offset and, as shown in the Supplementary Material (S1; available online)
Recall that c is the center-specific prevalence, c ¼ PðD ¼ 1jC ¼ cÞ:
Returning to the general linear-logistic model given in equation (6) , suppose that the model holds, but c 0 is not allowed to vary across centers. That is, suppose we fit the following model to the data pooled across centers:
When C and D are independent conditional on X or C and X are independent conditional on D, and model (6) holds, we have collapsibility, 44 so the conditional and marginal coefficients are the same (a ¼ b) and the marginal logit, logitfPðD ¼ 1jXÞg, is still linear. Therefore, in these situations, the relationship between the biomarkers and the outcome is the same whether or not we condition on center. Furthermore, under model (6), when C and D are independent conditional on X, c 0 will not vary across centers, so 0 ¼ c 0 . However, when model (6) holds but C and D are not independent conditional on X and C and X are not independent conditional on D, we may no longer have a ¼ b. Furthermore, the linear-logistic model (6) may not hold, in which case the results on collapsibility will no longer be expected to apply. More generally, ignoring center in the construction of the biomarker combination potentially allows center to be predictive; that is, part of the effect of center may be included in the estimates of the biomarker coefficients when center is omitted.
Center may also be ignored in the evaluation of combinations. Suppose we have a linear combination, L h ðXÞ ¼ h > X. When center is ignored in the evaluation of L h ðXÞ, the data are pooled across centers, giving the marginal AUC,
is associated with center, the marginal AUC may not reflect the center-specific AUC. 34 
Accounting for center
Analogous to center-adjusted measures of association in multicenter etiologic studies and centeradjusted treatment effects in multicenter randomized trials, methods that stratify (condition) on center can be used in both the construction and evaluation of biomarker combinations. By stratifying on center, we avoid allowing center differences to affect the construction of the biomarker combination or the assessment of its performance.
Construction
We consider two methods for constructing combinations that involve conditioning on center, namely, RILR and FILR; for FILR, we will consider both cFILR and uFILR. For concreteness, we consider p ¼ 2 in the discussion below.
To the extent that the literature has acknowledged the potential role of center in the prediction setting, RILR is often the approach used in constructing combinations:
where F is the distribution of the random center-specific intercepts. In general, when the distribution of X 1 or X 2 varies by center, assumption (A1) may not hold and the estimates ð 0 , 1 , 2 Þ may not be meaningful. An option that has been discussed at length in the literature on multicenter randomized trials, 1,11,17 but has been largely (if not entirely) neglected in the prediction literature is FILR, using uFILR when the number of centers is modest and cFILR when the number of centers is large:
Random intercept models are, at first glance, appealing in the context of prediction when the data arise from multiple centers: these models are thought to represent a situation where there exists a large population of centers, and the data at hand constitute a random draw of centers from that population. This intuition may make investigators more comfortable with generalizing their results to centers not included in their data, typically the goal of prediction research, and thus more likely to use RILR. However, the key distinction between random and fixed intercept models is not necessarily whether the center-specific intercepts are random or fixed, but rather whether they are associated with the biomarkers. 8 Thus, while the notion of center-specific intercepts as random quantities may have intuitive appeal, this is outweighed by the fact that random intercept models rely on potentially untenable assumptions.
Researchers may also be drawn to RILR since it gives an estimate of the overall intercept 0 and, since the center-specific intercepts b c are typically assumed to be normally distributed with mean 0, researchers may usê 0 þ 1 X 1 þ 2 X 2 to provide predicted probabilities for patients in new centers not used in model fitting. However, assuming b c ¼ 0 in new centers generally leads to poor calibration; that is, it does not provide useful estimates of PðD ¼ 1jXÞ. 21 Even if a valid estimate of b c is available, the estimate of 0 from RILR can be badly biased if the random intercept distribution is misspecified.
The ''poor man's'' method has been proposed as an alternative to standard RILR. Even if the distributions of the mean-centered predictors are the same across centers (which would help to address violations of assumption (A1)), this method is not particularly compelling in the prediction setting since application of the model to new centers requires estimates of the center-specific biomarker means; such reliance on information from the new center makes external validation and clinical application (if predicted probabilities are sought) more challenging. In addition, since the ''poor man's'' method still relies on a RILR model, the estimate of the fixed intercept may face the same challenges as with the standard RILR model.
The goal of the ''poor man's'' method is to transform the biomarkers into predictors that are independent of b c . This is an attempt to force the model to estimate the within-center effect of the biomarkers, as opposed to a combination of the within-and between-center effects. However, FILR estimates the within-center effect with no further assumptions or transformations of the data. This is compelling as estimates of biomarker associations (and thus, fitted biomarker combinations) that are unaffected by center differences are most useful in identifying promising combinations for further development.
Conversely, an obvious criticism of FILR is that it does not allow predicted probabilities to be calculated either in new centers (for uFILR) or at all (for cFILR). However, as discussed above, RILR does not necessarily solve this problem. Furthermore, the biomarker combination estimated by FILR can still be useful, for example, to stratify patients within each center according to likelihood of having or developing the outcome.
Evaluation
The marginal AUC would be an appropriate measure of performance if between-center heterogeneity could be used in making decisions, but this is not typically true. 46 Thus, some summary of the conditional, or centerspecific, AUCs should be used to avoid allowing center differences to influence the evaluation of performance; we propose using the center-adjusted AUC defined in equation (4) . For a given combination L h ðXÞ ¼ h > X, the center-adjusted AUC can be written as aAUCðhÞ ¼ P M c¼1 w c AUC c ðhÞ where the center-specific AUC is
ÞÞ. Note that only discordant centers contribute to the empirical estimate of the center-adjusted AUC defined in equation (5) .
When the ROC curve varies by a covariate, it is generally recommended that a separate ROC curve be estimated for each value of the covariate. 36 In the case of center, where only a fraction of the centers are observed, this is not possible. However, it is reasonable to assess the heterogeneity in the center-specific AUCs, as this provides some indication of how the predictor may perform in a new center. 45 Finally, as a consequence of focusing on the center-specific AUC, summarized via the aAUC, we do not need an estimate of the center-specific intercept to evaluate a combination, as the center-specific AUC is a rank-based measure and so would be unaffected by such offsets. This allows for identification of promising combinations of biomarkers for further development without the need for center-specific intercept estimates.
Asymptotic properties
Our proposal involves constructing linear combinations of biomarkers by estimating h and evaluating the performance of these combinations with the aAUC. We would like to demonstrate consistency of this estimate of performance; that is, we would like to say that aAÛCðĥÞ converges in probability to aAUCðh 0 Þ ifĥ converges in probability to h 0 . This is shown by Lemma 1 and Theorems 1 and 2, which are stated and proved in the Supplementary Material (S2; available online).
Combining construction and evaluation
When constructing and evaluating biomarker combinations, there are two binary decisions to make regarding center, giving four possibilities (using the notation of models (6) and (8)): (a) Pool the data across centers for both construction and evaluation, giving AUCðaÞ; (b) Pool the data across centers for construction, but stratify by center for evaluation, giving aAUCðaÞ; (c) Stratify by center for construction, but pool across centers for evaluation, giving AUCðbÞ; (d) Stratify by center for both construction and evaluation, giving aAUCðbÞ.
Proposition 1, given in the Supplementary Material (S3; available online), follows directly from Pepe 33 and shows that the marginal and center-adjusted AUCs of a combination based on some h are equivalent if C and L h ðXÞ are independent among controls. If C and X are independent conditional on D, then C and L h ðXÞ will be independent among controls. Thus, if model (6) holds and C and X are independent conditional on D, then AUCðbÞ ¼ aAUCðbÞ ¼ aAUCðaÞ ¼ AUCðaÞ, since a ¼ b by collapsibility. Proposition 2, given in the Supplementary Material (S3; available online), also follows directly from Pepe 33 and shows that when the prevalence and center-specific AUC do not vary with center and the center-specific ROC curves are concave, the aAUC for a given biomarker combination will be at least as large as the marginal AUC. In general, the centerspecific ROC curves will be concave if for a given h, in each center, increasing L h ðXÞ increases the likelihood that D ¼ 1. 37 When model (6) holds, optimality of the risk score PðD ¼ 1jX, C ¼ c, c 0 Þ implies that the combination based on b is optimal within each center, in terms of maximizing the center-specific AUC. 33, 47 Thus, under this model, aAUCðbÞ ! aAUCðhÞ for any h. Furthermore, by the collapsibility results discussed above, when model (6) holds and C and D are independent conditional on X, a ¼ b, so AUCðaÞ ¼ AUCðbÞ aAUCðaÞ ¼ aAUCðbÞ
Identifying the role of center
When biomarker data from multiple centers are available, graphical displays and other data summaries may be useful for identifying whether center is a case mix variable, calibration variable, or confounder.
We therefore propose investigating:
(a) The distribution of the biomarkers across center (to assess whether C?X); (b) The distribution of the biomarkers across center stratified by the outcome (to assess whether C?XjD); (c) The prevalence of the outcome across centers (to assess whether C?D); (d) The prevalence of the outcome across centers, stratified by biomarker categories (to assess whether C?DjX).
Not all of these tools will be useful in all settings; for example, in the case of diagnostic biomarkers, (b) and (c) will be most useful, while (a) and (d) will be most useful for prognostic markers. Also, implementing (d) may be challenging as it requires the designation of biomarker categories, which necessarily results in a loss of information. Alternatively, this relationship could be assessed with a regression model. Some of these suggestions are similar in spirit to those made by Berlin et al. in the setting of a single binary predictor. 17 It is important to keep in mind that there are no ''rules'' for interpreting the results of the data summaries proposed above. Rather, they should be used as a guide, in conjunction with knowledge about the design and conduct of the study, to assess the role of center.
Simulations 6.1 Ignoring center
We studied the impact of ignoring center in the construction and/or evaluation of biomarker combinations. We considered diagnostic markers, and allowed center to be a case mix variable, a calibration variable, or a confounder (as summarized in Figure 1 ). The two biomarkers X 1 and X 2 were distributed as described in equation (7) (8) and (6)), respectively.
We evaluated fitted combinations via the conditional AUC, AUC c ðÁÞ, in a large test dataset with a single center, and the marginal AUC, AUCðÁÞ, in a large test dataset with multiple centers. As shown in the Supplementary Material (S4; available online), the conditional AUC is constant across centers under our data-generating model, so AUC c ðÁÞ ¼ aAUCðÁÞ. The test set used to evaluate the conditional AUC consisted of a single center with 200,000 observations while the test set used to evaluate the marginal AUC included either 6 centers with 30,000 observations each or 500 centers with 400 observations each, depending on the structure of the training data. The observations in the test data represent subjects from new centers, i.e. not the same centers as used in the training data. The true coefficients b ¼ ð 1 , 2 Þ and AUC c ðbÞ were determined analytically for comparison. The simulations were repeated 500 times. Figure 2 presents the results of the simulations with 500 centers. These simulations support the conclusions given above: that is, when center was a case mix variable, the combination and its performance (in terms of the AUC) were not affected by ignoring center in construction and/or evaluation. When center was a calibration variable, ignoring center during construction led to biomarker combinations with reduced predictive capacity in new centers, and ignoring center during evaluation yielded a measure of performance that was lower than the performance of the combination in a new center. These results are consistent with the relationships described above, that is, AUC c ðbÞ ! AUC c ðâÞ, AUC c ðbÞ ! AUCðbÞ, and AUC c ðâÞ ! AUCðâÞ.
When center was a confounder and center was ignored during construction (yieldingâ), further ignoring center during evaluation tended to give a measure of performance that was higher than the performance in a new center (i.e. AUCðâÞ tended to be larger than AUC c ðâÞ). On the other hand, if center was included in construction (yieldinĝ b), ignoring center during evaluation gave a measure of performance that could be higher or lower than the performance of the combination in a new center; that is, AUCðbÞ tended to be larger or smaller than AUC c ðbÞ, considerably larger when center was a calibration variable than when it was a confounder. The full results are given in the Supplementary Material (S5.2; available online). In general, we see that the differences between RILR and FILR tended to be smaller when there were fewer centers (m ¼ 6 vs. m ¼ 500), was large. The superior performance of FILR persisted even when we considered situations where there were 500 centers and, on average, 7-12% were concordant (Supplementary Material S5.2; available online). In simulations not designed specifically to have high concordance, up to 2% of centers were concordant, on average. Finally, we evaluated the estimate of the overall fixed intercept provided by RILR and found absolute biases of more than 20% in many scenarios (Supplementary Material S5.2; available online).
We have provided the R functions used to conduct these simulations in the Supplementary Material (S6; available online).
Application to the TRIBE-AKI Study
We applied the methods we have discussed to data from the TRIBE-AKI study. Recall that this is a study of 1219 adults undergoing cardiac surgery at six medical centers, and there is interest in using biomarkers to provide an earlier diagnosis of post-operative AKI. All participants provided written informed consent and details regarding subject recruitment and sample collection and storage have been previously reported. 5 These data are used as illustration and not to report new findings of the TRIBE-AKI study. We considered three biomarkers, urine NGAL, plasma h-FABP, and plasma TNI, and used the measurements taken immediately after surgery. After removing observations with missing values for any of these biomarkers, 962 observations remained. The three biomarkers were log-transformed.
First we assess the role of center in this study. Since we are considering diagnostic biomarkers, we evaluated the distribution of the biomarkers in each center among AKI controls, and found variation in these distributions across centers (Figure 4) . Additionally, the center-specific AKI prevalences were between 7.8% and 22.9%. These results strongly suggest that center is a confounder in this study.
We constructed linear biomarker combinations and evaluated their performance by estimating the centeradjusted AUC. We corrected this estimate for resubstitution bias by bootstrapping the individual observations. The optimism-corrected center-adjusted AUC for this combination was 0.6806 (0.6328, 0.7337). When center was ignored during construction, the estimated combination was 0:081 Ã logðNGALÞ þ 1:103 Ã logðh-FABPÞ À 0:094 Ã logðTNIÞ and the optimism-corrected center-adjusted AUC for this combination was 0.6811 (0.6321, 0.7349). Thus, in these data, the three fitted combinations were quite similar, and, correspondingly, the gains offered by FILR in terms of the center-adjusted AUC were very modest.
Discussion
We have created a unified framework for constructing and evaluating biomarker combinations in multicenter studies, including a taxonomy to differentiate the role center can play, tools for identifying the role of center, and methods for constructing a biomarker combination and evaluating its performance. Essentially, by conditioning on center in both the construction and evaluation of biomarker combinations, we obtain combinations and measures of performance that are unaffected by center differences. Given that such center differences are often not scientifically relevant and are expected to vary in magnitude from center to center, using conditional approaches for construction and evaluation of biomarker combinations is advised in order to avoid allowing center differences to influence either the combination itself or the assessment of its performance. The concepts and methods we describe apply to biomarker combinations and also to combinations of biomarkers and clinical or demographic variables.
The center-specific AUC may not be the same across centers; in this situation, it is generally informative to evaluate the variability in the center-specific AUCs across centers. This offers some indication of how the biomarker combination might be expected to perform in a new center, if the centers included in the evaluation are ''similar'' to the new centers. However, when assessing the center-specific AUCs, it is important to keep in mind that AUC estimates from centers with fewer observations are less reliable.
Different sampling schemes could affect the estimated weightsŵ c , which could in turn affect the estimated center-adjusted AUC. The center-specific AUC itself is unaffected by case-control sampling within each center 41 and the center-adjusted AUC is unaffected by center-dependent sampling among controls, 35 though the asymptotic results we have provided may not hold under certain sampling schemes. If a multicenter study also involves matching, care must be taken to adjust the AUC for the matching in addition to center. 34 The issues discussed in this paper are to some degree applicable to continuous and survival outcomes. For continuous outcomes, within the linear model framework, when the random intercept model EðYjX, C ¼ c, b c Þ ¼ b c þ 0 þ 1 X holds, the fixed parameters ð 0 , 1 Þ are equivalent to the parameters from a marginal model. However, when the assumptions of this random intercept model are violated, differences between within-and between-center effects may lead to some of the same issues described above. 11 For survival outcomes, in the proportional hazards framework, the frailty model is the analogue of the RILR model and the (stratified) Cox model is the analogue of the FILR model. The frailty model makes some of the same assumptions as the RILR model, including independence of the random intercept and the predictors. The issue of bias resulting Figure 4 . Distribution of log urine NGAL, log plasma h-FABP, and log plasma TNI in the TRIBE-AKI study among controls. The biomarker distributions are stratified by center.
from violations of this assumption is not well explored in the literature, but the occurrence of such bias certainly seems plausible.
Future research will consider approaches that do not rely on empirical estimates of the center-specific AUC, perhaps by modeling the fitted combination parametrically (e.g. using a model to relate the combination to center among controls) 36 ; such an approach may be useful when there are a large number of very small centers, as might happen when the ''centers'' are clinicians. In these settings, the empirical center-specific AUC estimate may be unreliable, and an alternative estimate may be preferable.
An important contribution of this work is that it demonstrates that methods often applied to multicenter biomarker data are frequently not appropriate. Biomarkers hold great potential for use as diagnostic and prognostic tools, but have for the most part been relatively disappointing thus far. Much of the problem has been blamed on ''validation failures''; that is, biomarkers that are found to be quite promising initially, but are never used in clinical practice due to disappointing results in follow-up studies. 48 Thus, to the extent possible, it is important to recognize aspects of study design, conduct, and analysis that require special attention when developing biomarker combinations. Carefully addressing these issues can increase the likelihood of identifying clinically useful combinations, ultimately leading to improvements in patient care.
